Your browser doesn't support javascript.
loading
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
Ambrosioni, Juan; Levi, Laura; Alagaratnam, Jasmini; Van Bremen, Kathrin; Mastrangelo, Andrea; Waalewijn, Hylke; Molina, Jean-Michel; Guaraldi, Giovanni; Winston, Alan; Boesecke, Christoph; Cinque, Paola; Bamford, Alasdair; Calmy, Alexandra; Marzolini, Catia; Martínez, Esteban; Oprea, Cristiana; Welch, Steven; Koval, Anna; Mendao, Luis; Rockstroh, Jürgen K.
Afiliación
  • Ambrosioni J; HIV Unit, Infectious Diseases Service, Hospital Clinic-Fundació de recerca Clinic Barcelona - Institut de investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.
  • Levi L; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
  • Alagaratnam J; Department of Infectious Diseases, St-Louis and Lariboisière Hospitals, APHP, University of Paris Cité, Paris, France.
  • Van Bremen K; HIV Medicine & Sexual Health, Chelsea & Westminster Hospital NHS Foundation Trust, London, UK.
  • Mastrangelo A; Section of Virology, Department of Infectious Disease, Imperial College London, London, UK.
  • Waalewijn H; Department of Medicine I, Bonn University Hospital, Bonn, Germany.
  • Molina JM; Allergology and Immunology Department, Centre Hopitalier Universitaire Vaudoise (CHUV), Lausanne, Switzerland.
  • Guaraldi G; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Winston A; Department of Infectious Diseases, St-Louis and Lariboisière Hospitals, APHP, University of Paris Cité, Paris, France.
  • Boesecke C; Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Cinque P; Section of Virology, Department of Infectious Disease, Imperial College London, London, UK.
  • Bamford A; Department of Medicine I, Bonn University Hospital, Bonn, Germany.
  • Calmy A; Unit of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy.
  • Marzolini C; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Martínez E; HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
  • Oprea C; Departments of Medicine and Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Welch S; Service of Clinical Pharmacology, University Hospital Lausanne and University of Lausanne, Lausanne, Switzerland.
  • Koval A; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
  • Mendao L; HIV Unit, Infectious Diseases Service, Hospital Clinic-Fundació de recerca Clinic Barcelona - Institut de investigacions Biomediques August Pi i Sunyer, Barcelona, Spain.
  • Rockstroh JK; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
HIV Med ; 24(11): 1126-1136, 2023 11.
Article en En | MEDLINE | ID: mdl-37849432
ABSTRACT

BACKGROUND:

The European AIDS Clinical Society (EACS) guidelines were revised in 2023 for the 19th time, and all aspects of HIV care were updated. KEY POINTS OF THE GUIDELINES UPDATE Version 12.0 of the guidelines recommend the same six first-line treatment options for antiretroviral treatment (ART)-naïve adults as versions 11.0 and 11.1 tenofovir-based backbone plus an unboosted integrase inhibitor or doravirine; abacavir/lamivudine plus dolutegravir; or dual therapy with lamivudine or emtricitabine plus dolutegravir. The long-acting section has been expanded in the ART and drug-drug interaction (DDI) panels. Tables for preferred and alternative ART in children and adolescents have been updated, as has the section on prevention of vertical transmission, particularly with new guidance for breastfeeding. A new DDI table has been included for the ART and anti-infective drugs used for opportunistic infections, sexually transmitted infections, and other infectious conditions; lenacapavir has been included in all DDI tables. New sections on alcohol use and patient-reported outcome measures (PROMs) have been included in the comorbidity panel, in addition to updates on many relevant topics, such as new resource guidance for deprescribing in people with HIV. Other sections, including travel, cognitive impairment, cancer screening, sexual health, and diabetes have also been revised extensively. The algorithm for the management of acute hepatitis C virus infection has been removed, as current guidelines recommend immediate treatment of all people with recently acquired hepatitis C virus. Updates on vaccination for hepatitis B virus and recommendations for simplification to tenofovir-free two-drug regimens in people with isolated anti-hepatitis B core antibodies are provided. In the opportunistic infections and COVID-19 panel, guidance on the management of COVID-19 in people with HIV has been updated according to the most up-to-date evidence, and a new section on monkeypox has been added.

CONCLUSIONS:

In 2023, the EACS guidelines were updated extensively and now include several new sections. The recommendations are available as a free app, in interactive web format, and as a pdf online.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Síndrome de Inmunodeficiencia Adquirida / Hepatitis C / Infecciones Oportunistas Relacionadas con el SIDA / Fármacos Anti-VIH / COVID-19 Límite: Adolescent / Adult / Child / Humans Idioma: En Revista: HIV Med Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2023 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / Síndrome de Inmunodeficiencia Adquirida / Hepatitis C / Infecciones Oportunistas Relacionadas con el SIDA / Fármacos Anti-VIH / COVID-19 Límite: Adolescent / Adult / Child / Humans Idioma: En Revista: HIV Med Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2023 Tipo del documento: Article País de afiliación: España